CNS Pharmaceuticals, Inc. (CNSP)
Stock Price:
$2.02 USD
0.15 (8.02%)
Updated Jul 16, 2020 1:54 PM EDT - Market open
Key Info
| Market Cap |
33.23M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-5.63M |
| Shares Out |
16.45M |
| EPS (ttm) |
-0.64 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 16, 2020 |
| Last Price |
$2.02 |
| Previous Close |
$1.87 |
| Change ($) |
0.15 |
| Change (%) |
8.02% |
| Day's Open |
1.95 |
| Day's Range |
1.85 - 2.05 |
| Day's Volume |
49,529 |
| 52-Week Range |
1.26 - 5.69 |
More Stats
| Market Cap |
33.23M |
| Enterprise Value |
27.85M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
16.45M |
| Float |
6.49M |
| EPS (basic) |
-0.38 |
| EPS (diluted) |
-0.64 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
100,624 |
| Short Ratio |
0.88 |
| Short % of Float |
1.57% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
5.24 |
| Revenue |
n/a |
| Operating Income |
-5.61M |
| Net Income |
-5.63M |
| Free Cash Flow |
n/a |
| Net Cash |
5.38M |
| Net Cash / Share |
0.33 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-103.60% |
| ROE |
-218.44% |
| ROIC |
9,065.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
11.0
Current: 2.02
High
11.0
Target: 11.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -3.83 | -0.88 |
| Net Income | -3.88 | -7.39 |
| Shares Outstanding | 13.65 | 10.51 |
| Earnings Per Share | -0.28 | -0.70 |
| Operating Cash Flow | -3.55 | -0.72 |
| Capital Expenditures | -0.02 | - |
| Free Cash Flow | -3.57 | -0.72 |
| Cash & Equivalents | 7.24 | 0.56 |
| Total Debt | - | 0.32 |
| Net Cash / Debt | 7.24 | 0.24 |
| Assets | 7.91 | 0.68 |
| Liabilities | 0.31 | 1.23 |
| Book Value | 7.60 | -0.55 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
CNS Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
3 |
| CEO |
John M. Climaco |
Stock Information
| Ticker Symbol |
CNSP |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CNSP |
Description
CNS Pharmaceuticals, Inc., a preclinical stage pharmaceutical company, focuses on the development of anti-cancer drug candidates for the treatment of primary and metastatic brain, and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma. It has a development agreement with WPD Pharmaceuticals Inc. for the development of several preclinical drug candidates including WP1122, which will be tested on a range of viruses, including the coronavirus SARS-CoV-2. CNS Pharmaceuticals, Inc. was founded in 2017 and is based in Houston, Texas.